Àº»ê¹Ìµð¾î

Âü°í¼­ÀÇÇÐ > Âü°í¼­

Àü¹®°¡Æò°¡ :
ÆäÀ̽ººÏ °øÀ¯Çϱâ Æ®À§ÅÍ·Î °øÀ¯Çϱâ Ä«Ä«¿À½ºÅ丮 °øÀ¯Çϱâ

The Clozapine Handbook:Stahl's Handbooks

  • Á¤ °¡65,900¿ø

    ÆǸŰ¡65,900¿ø(100%¡é, 0¿ø ÇÒÀÎ)

  • ÃâÆÇ»çCambridge

    ÀúÀÚMeyer

    ISBN9781108447461

    ÃâÆdz⵵2019-08-01

    ÆäÀÌÁö326page

  • ¼ö ·® Áõ°¡ °¨¼Ò
ÃÑ ÇÕ°è±Ý¾×65,900¿ø

Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.

The increased interest in promoting greater clozapine use internationally means this book fills a gap in the market for clinicians who seek evidence-based advice on best practices

Use of clozapine has shown real world benefits such as a reduction in suicidality, psychiatric hospitalization and mortality rates. Many clinicians are unfamiliar with recent improvements in the understanding of clozapine-related dosing and adverse effect management 

Provides a logical, evidence-based framework for important clinical issues - this handbook leads the clinician through the reasoning process for adverse effect management and other common clinical situations


¹è¼Û¾È³» 

- »óÇ°¼ö·É ±â°£Àº ÀԱݿϷáÈÄ 2~3ÀÏ À̳»¿¡ ¹è¼ÛÀÌ ¿Ï·áµÇ¸ç (¿µ¾÷ÀÏ ±âÁØ, °øÈÞÀÏ ¹× õÀçÁöº¯Àº Á¦¿Ü) ÁÖ¹®ÇϽŠ»óÇ°¿¡ µû¶ó ¹è¼Û±â°£ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.
- ÇØ¿ÜÁÖ¹®À¸·Î ÁøÇàµÉ °æ¿ì 4~5ÁÖ ¼Ò¿ä µÉ ¼ö ÀÖ½À´Ï´Ù.
- »óÇ°±¸¸Å ±Ý¾×ÀÌ 25,000¿ø ¹Ì¸¸ÀÎ °æ¿ì ¹è¼Ûºñ 3,000¿øÀ» ºÎ´ãÇÏ¼Å¾ß ÇÕ´Ï´Ù.
- µµ¼­»ê°£Áö¹æÀº ±âº» ¹è¼Ûºñ ÀÌ¿Ü¿¡ Ãß°¡ ¹è¼Ûºñ°¡ Ãß°¡µÉ ¼ö ÀÖ½À´Ï´Ù.
- ÁÖ¹®ÇϽŠ»óÇ°Àº ·ÎÁ¨Åùè·Î ¹è¼ÛµÇ¸ç ÁÖ¹®/¹è¼ÛÁ¶È¸¿¡¼­ ¹è¼ÛÇöȲÀ» Á¶È¸ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.

Ãë¼Ò/±³È¯/¹ÝÇ°¾È³»
- ÀÔ±Ý/°áÁ¦¿Ï·á ÀÌÀü¿¡´Â ¹Ù·Î ÁÖ¹®/¹è¼ÛÁ¶È¸¿¡¼­ Ãë¼ÒÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
- ÀÔ±Ý/°áÁ¦ ¿Ï·á½Ã ÀÔ±ÝÈ®ÀÎ °Ô½ÃÆÇ ¶Ç´Â °í°´¼¾ÅÍ(02-739-9531)·Î ¿¬¶ôÁֽøé Ãë¼Ò/±³È¯/¹ÝÇ°ÀÌ °¡´ÉÇÕ´Ï´Ù.
- »óÇ°ÀÇ ÇÏÀÚ°¡ Àִ°æ¿ì ¼ö·ÉÈÄ 7ÀÏ À̳» ±³È¯ ¹× ¹ÝÇ°ÇÏ½Ç ¼ö ÀÖÀ¸¸ç ¹è¼Ûºñ´Â ¼îÇθô¿¡¼­ ºÎ´ãÇÕ´Ï´Ù.
- Æ÷Àå ¶Ç´Â ³»¿ë¹°ÀÌ ÈÑ¼ÕµÇ¾î »óÇ°°¡Ä¡°¡ »ó½ÇµÈ °æ¿ì ¹ÝÇ°±³È¯ÀÌ ºÒ°¡´ÉÇÕ´Ï´Ù.
- °í°´´ÔÀÇ ¸¶À½ÀÌ ¹Ù²î¾î ±³È¯/¹ÝÇ° ½Ã ¿Õº¹ ¹è¼Û·á´Â °í°´´ÔºÎ´ãÀÔ´Ï´Ù.